Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia

NCT00345345 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

29

Enrollment

NIH

Sponsor class

Conditions

T-LGL Lymphoproliferative Disorders

Interventions

BIOLOGICAL: Alemtuzumab (Campath)

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)